InflaRx Names Experienced Nephrologist to Lead Clinical Development of Complement-Targeting Therapeutics
InflaRx has appointed Dr. Gabriela Alperovich as Senior Vice President and Global Head of Clinical Development, effective October 1, 2026. Alperovich brings over 20 years of pharmaceutical industry experience, including successful advancement of Phase 2 and registrational programs in immune-inflammatory renal diseases. Her expertise in complement-driven disorders positions her to guide the advancement of izicopan and expand the company's pipeline in treating diseases with significant unmet medical needs.
Dr. Alperovich's appointment underscores InflaRx's commitment to advancing its complement-targeting platform. Her previous leadership roles at major pharmaceutical companies including CSL Vifor, AbbVie, and Bristol-Myers Squibb involved bringing multiple kidney-related therapies through regulatory approval, including treatments for IgA nephropathy and focal segmental glomerulosclerosis. This track record in navigating complex registrational pathways for renal and immune-inflammatory conditions directly aligns with InflaRx's clinical strategy.
Izicopan, the company's lead candidate, represents a potential advancement in complement inhibition therapy. The drug's oral formulation and favorable drug-interaction profile—particularly its lack of significant CYP3A4 inhibition, which distinguishes it from existing C5aR inhibitors—may reduce complications in treating patients who require concurrent medications. Early human studies indicated tolerability across a wide dosage range without identified safety concerns.
This appointment could facilitate faster clinical progression for complement-targeted therapies in kidney diseases with limited treatment options. Patients with conditions like ANCA-associated vasculitis and lupus nephritis may potentially benefit if izicopan advances successfully through development and regulatory approval. The leadership transition may also influence how effectively InflaRx builds its pipeline in immune-inflammatory disorders, though clinical outcomes will ultimately depend on trial results and regulatory evaluation rather than personnel decisions alone.